The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells ... PR Carbon (press release) Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are ... |
